TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02844998

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity
Description: patients will do moderate running which make them breathe somewhat harder than normal for at least 30 minutes for 5 days in a week

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: physical activity
Description: patients will do moderate running which make them breathe somewhat harder than normal for at least 30 minutes for 5 days in a week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dapoxetine 30 mg on demand
Description: Dapoxetine, a short-acting selective serotonin reuptake inhibitors, has been utilized for the treatment of premature ejaculation in various countries
Study: NCT03094195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMA401
Description: EMA401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMA401
Description: EMA401

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00529737

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breast Biopsy
Description: Stereotactic-guided breast biopsy via standard practice of care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breast Biopsy
Description: Stereotactic-guided breast biopsy via standard practice of care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post Procedure Mammogram
Description: View of post-procedure mammogram same projection as used in the biopsy procedure (View A), and mammographic view orthogonal projection to the first view (View B).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post Procedure Mammogram
Description: View of post-procedure mammogram same projection as used in the biopsy procedure (View A), and mammographic view orthogonal projection to the first view (View B).
Study: NCT00360399

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram 10 to 20 mg per day for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: Duloxetine 30 to 60 mg per day for 12 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy (CBT)
Description: CBT will include 16 one-hour sessions provided over 12 weeks.
Study: NCT03016780

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fecal Microbiota Transplantation
Description: Fecal microbiota transplantation and the traditional treatments for ulcerative colitis in part 1.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal saline and the traditional treatments for ulcerative colitisin in part 2.
Study: NCT04553107

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deprescribing Intervention
Description: An individualized deprescribing intervention will be created by a pharmacist working with a patient to identify harmful, costly, and unnecessary medications to be reduced. The intervention will include a plan and monitoring for up to 3 months to reduce medication use.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: The usual care arm will receive the current standard of care, which includes medication reconciliation by a clinic nurse at the time of their appointment. Nurses review all medications and answer medication-related questions, and refer medication questions to the healthcare provider for further discussion when necessary.
Study: NCT01497262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod
Description: Fingolimod will be supplied as 0.5mg capsules in bottles of 35.
Study: NCT03005626

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic education

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard follow-up
Study: NCT03004807

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Centrum Silver Mens' Formula
Description: Multivitamin/Multimineral dietary supplement produced for Pfizer for use in older men.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: A matching tablet to the dietary supplement, but without any active ingredients
Study: NCT05610371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: The study group underwent hysteroscopy using saline to which 10ml of 2% lidocaine was added to the first 1000 ml. This dose of lidocaine was calculated to allow maximal benefits with minimal potential complications. The maximal dose of lidocaine is 5mg\\kg in adults which translates to 200mg in a 40kg patient. We have set 200 mg as the maximal dose of lidocaine in our study, assuring the dosage is safe. The rest of the procedure following the first 1000ml of saline was completed using saline alone as needed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: The control group underwent hysteroscopy using a saline distension medium.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: The control group underwent hysteroscopy using a saline distension medium.
Study: NCT01752023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin + Gemcitabine with SUBATM-itraconazole
Description: Experimental Arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin + Gemcitabine
Description: Active Comparator
Study: NCT04112680

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Debunking Misinformation through Audio Dramas
Description: The audio dramas (one drama of 4 episodes per intervention group), aim to debunk misinformation about an infectious disease. The content of the two dramas differ in the two groups; in intervention group 1, the drama will state the misinformation and provide a plausible alternative, delivered through a trusted source, in line with world views. In intervention group 2, the audio drama will avoid mentioning the misinformation and instead only state the correct information about the infectious disease

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Debunking Misinformation through Audio Dramas
Description: The audio dramas (one drama of 4 episodes per intervention group), aim to debunk misinformation about an infectious disease. The content of the two dramas differ in the two groups; in intervention group 1, the drama will state the misinformation and provide a plausible alternative, delivered through a trusted source, in line with world views. In intervention group 2, the audio drama will avoid mentioning the misinformation and instead only state the correct information about the infectious disease

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control group audio jingles
Description: The control group will receive audio jingles about exclusive breastfeeding
Study: NCT02445833

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle on-line intervention
Description: The self-applied on-line intervention will comprise a behavioural intervention composed by 9 modules seeking to develop gradually achieving the goals of changing eating habits and physical activity in participants (Themes: 1.motivation for change; 2. nutrition and physical activity education; 3. barriers to change, healthy eating principles and how to be active; 4. Influence of thoughts; 5. Emotional eating and self-control; 6. Problem solving; 7. Body image and assertiveness; 8. Relapse prevention)..The program will be established as follows: The first day the participant log in the website where can access the processing modules. A web page was developed specially for this study.
Study: NCT05535179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: honeysuckle and semen oroxyli solution
Description: The patients in the treatment group were instructed to gargle the solution containing honeysuckle and semen oroxyli (25 mL) four times a day for 2 weeks.
Study: NCT03845387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KDT-3594
Description: oral administration, dose titration

Intervention type: DRUG
Group type: OTHER
Intervention: Pramipexole
Description: ER formulation, oral administration, dose titration
Study: NCT05190952

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine 0.25% 1ml/kg will be injected subcutaneously by the surgeon before wound closure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine 0.25% 1ml/kg will be injected subcutaneously by the surgeon before wound closure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine 0.25% 1ml/kg will be injected subcutaneously by the surgeon before wound closure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: In addition to bupivacaine, ketamine 1mg/kg diluted in 10 ml normal saline will be injected subcutaneously by the surgeon before wound closure. Bupivacaine and ketamine will be administered using two separate syringes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: In addition to bupivacaine, dexamethasone 0.2mg/kg diluted in 10 ml normal saline will be injected subcutaneously by the surgeon before wound closure. Bupivacaine and dexamethsone will be administered using two separate syringes.
Study: NCT02787772

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Elective Hernia repair
Description: abdominal wall hernia repair using onlay mesh.
Study: NCT03871478

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: See Arm Description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: See Arm Description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine and Bupivacaine
Description: See Arm Description
Study: NCT02567526

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Between-Meal Intervention Group
Description: Non-nursing staff trained as Feeding Assistants were responsible for supplement and snack delivery in the mornings and afternoons between meals supervised by research staff
Study: NCT01597102

Intervention type: OTHER
Intervention: No interventions
Description: No intervention is planned in this study
Study: NCT03644160

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity and behaviour change
Description: The intervention group (group A) will receive an 8 week individualised, tailored behaviour change intervention to promote PA and an information booklet about physical activity to include an initial 1:1 session with a physiotherapist with training in behaviour change techniques and motivational interviewing. Using a range of behaviour change and self-regulation techniques (eg goal-setting, self-monitoring), participants will be guided towards physical activity maintenance at the end of the 8 weeks. In addition, participants will be signposted to physical activity classes, facilities and resources in the local community. This group will continue with their routine care for their condition throughout the study period.
Study: NCT02667145

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self care program focusing on the assistive device
Description: self-heed program focusing on the assistive device will consist of four weekly meetings lasting approximately 90 minutes. it will be stimulated the self-heed through knowledge of pathology and guidelines of protection articulate, and will be supplied, and trained the use of assistive devices to improve the performance of volunteers in their daily activities. Assistive devices are devices, not attached to the body, which help people with limited movements and restrictions on participation in the activities of everyday life. Example: thickening of tableware, tin openers. These volunteers will be evaluated in three stages: 1-initial assessment 2-after completion of the program and 90 days after the initial assessment. The questionnaires that will be used are: EVA; SACRAH; COPM; WHOQOL-Bref.
Study: NCT01145937

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET
Description: Partial Endothelial Trepanation in addition to an anterior lamellar keratoplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DALK
Description: Conventional DALK grafting procedure, with Big Bubble technique according to Anwar et al.
Study: NCT04555941

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: intermittent theta burst stimulation
Description: active or Sham iTBS will be given to the AD/MCI patient

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intermittent theta burst stimulation
Description: active or Sham iTBS will be given to the AD/MCI patient
Study: NCT04523532

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary folate and hazelnut oil
Description: Intervention with folate-rich diet and hazelnut oil supplement in capsule

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dietary folate and hazelnut oil
Description: Intervention with folate-rich diet and hazelnut oil supplement in capsule

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary folate and hazelnut oil
Description: Intervention with folate-rich diet and hazelnut oil supplement in capsule
Study: NCT01508741

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 5-Aminolevulinic Acid (5-ALA)
Description: 5-ALA 50 mg. p.o. daily capsules taken over 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily p.o. capsule of similar shape and color to active ingredient 5-ALA capsule taken over 6 weeks.
Study: NCT01851733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood draw - dendritic cells
Description: The second 10 patients enrolled to Arm B:~* before MLA (up to 3 days before)~* 2 weeks after MLA~* 4 weeks after MLA~* every 2 weeks thereafter for up to 3 months after biopsy (provided there is no significant chemotherapy induced cytopenia)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Susceptibility Contrast Magnetic Resonance Imaging

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Susceptibility Contrast Magnetic Resonance Imaging
Study: NCT01614730

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Modified Neurotech Vital Device
Description: verify no contraction is stimulated in the Modified Neurotech Vital.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neurotech Vital Device
Description: Checking there is a contraction of the pelvic floor muscle when the treatment is administered with the Neurotech Vital Device
Study: NCT01874756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY500307 150mg
Description: LY500307 150mg daily dose (6 capsules of 25mg) for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY500307 75mg
Description: LY500307 75mg daily dose (3 capsules of 25mg and 3 capsules of placebo) for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 placebo capsules daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY500307 25mg
Description: LY500307 25mg daily dose (1 capsules of 25mg and 5 capsules of placebo) for 8 weeks
Study: NCT01173042

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Peanuts
Description: Shake containing 3.0oz of peanuts (including skin) + control (heavy whipping cream, glucose and chocolate syrup)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Glucose and whipping cream
Description: An oral liquid glucose (75g) and fat (high saturated fat from 60g heavy whipping cream) load. Chocolate syrup is added for flavor.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oil Blend
Description: Shake containing an oil blend (sunflower, sesame, olive and palm oils) + control (heavy whipping cream, glucose and chocolate syrup). The amount of oil added to the control will provide an equivalent amount of fat to that provided in 3 oz (85g) of peanuts
Study: NCT01678638

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IH repair before NICU discharge
Description: The IH repair is performed prior to NICU discharge (within 1-2 weeks of enrollment and randomization)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IH repair at 55-60 weeks post-menstrual age
Description: The IH repair will be performed as an outpatient between approximately 55-60 weeks post-menstrual age.
Study: NCT03535207

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: high dose chemoradiotherapy
Description: Radiation therapy: 50 Gy at 2 Gy/Fx/d on weeks 1-5,followed by 36 Gy in 30 fractions of 1.2 Gy, twice per day,on weeks 6-8 to a total dose of 86 Gy.~concurrent chemotherapy: weekly carboplatin area under the curve (AUC) 1.5-2 and paclitaxel 45-50 mg/m2 over the duration (8 weeks) of radiation therapy.~Adjuvant chemotherapy after high dose chemoradiation is optional.
Study: NCT01027143

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3 polyunsaturated fatty acids
Description: ProEPA Xtra 1000mg softgels: 3 softgels twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Omega-3 Fatty Acid
Description: Soybean oil: 3(age 12-25) matched softgel caps twice daily
Study: NCT00454909

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine 134612
Description: Single dose intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine 134612
Description: Single dose intramuscular injection.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menactra®
Description: Single dose intramuscular injection.
Study: NCT01475396

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Study: NCT00968552

Intervention type: PROCEDURE
Intervention: Self-expandable stent placement via endoscopy
Description: Self-expandable stent placement via endoscopy
Study: NCT04181190

Intervention type: DIAGNOSTIC_TEST
Intervention: Total IgE
Description: Levels of total IgE before biological treatments and at 4±2 months of treatments

Intervention type: DIAGNOSTIC_TEST
Intervention: Total IgE
Description: Levels of total IgE before biological treatments and at 4±2 months of treatments
Study: NCT04293744

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Colloid priming solution for ECC circuit
Description: Prospective, multi-center, double-blinded, randomized, controlled clinical trial

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard priming solution for ECC circuit
Description: Prospective, multi-center, double-blinded, randomized, controlled clinical trial
Study: NCT01605630

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-based family cancer literacy intervention
Description: family based counseling and materials provided in navajo/english including digital stories

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: standard of care
Study: NCT03060551

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SVF injection
Description: SVF is increasingly recognised as an easily accessible source of regenerative cells with therapeutic potential in ischaemic or autoimmune disease. We aimed to measure for the first time the safety, tolerability and potential efficacy of autologous SVF cells local injections in patients with systemic sclerosis
Study: NCT00888199

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental prosthetic foot (K3 Promoter)
Description: Experimental prosthetic foot

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental prosthetic foot (K3 Promoter)
Description: Experimental prosthetic foot
Study: NCT02929498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2879552
Description: GSK2879552 will be administered orally as continuous daily dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2879552
Description: GSK2879552 will be administered orally as continuous daily dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine will be administered at 75 mg/m2 from Day 1 to Day 7 of each 28 day cycle by intravenous (iv) infusion or subcutaneous (sc) injection.
Study: NCT01642615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole
Description: Dexlansoprazole capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole
Description: Dexlansoprazole capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dexlansoprazole placebo-matching capsules
Study: NCT02234518

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High quantity fiber
Description: The intervention type is food product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low quantity fiber
Description: The intervention type is food product

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02786823

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic acid
Description: tab. Folic acid 5 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic acid
Description: tab. Folic acid 5 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: tab. Vitamin B12 500 mcg

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: tab. Vitamin B12 500 mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral hypoglycemic agents [Metformin +/- Sulfonylurea]
Description: Patients receiving either of the following oral hypoglycemic agents~1. Sulfonylurea~2. Metformin~3. Metformin plus Sulfonylurea

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral hypoglycemic agents [Metformin +/- Sulfonylurea]
Description: Patients receiving either of the following oral hypoglycemic agents~1. Sulfonylurea~2. Metformin~3. Metformin plus Sulfonylurea

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral hypoglycemic agents [Metformin +/- Sulfonylurea]
Description: Patients receiving either of the following oral hypoglycemic agents~1. Sulfonylurea~2. Metformin~3. Metformin plus Sulfonylurea

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral hypoglycemic agents [Metformin +/- Sulfonylurea]
Description: Patients receiving either of the following oral hypoglycemic agents~1. Sulfonylurea~2. Metformin~3. Metformin plus Sulfonylurea
Study: NCT04451707

Intervention type: OTHER
Intervention: non-cholera Vibrio infection
Description: Epidemiology of patients diagnosed with non-cholera Vibrio infection
Study: NCT00814242

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical resection
Description: radical resection performed in patinets with HCC.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: percutaneous radiationfrequency ablation
Description: CT or Ultrasound-guided percutaneous radiofrequency ablation performed in patinets with HCC